Multiplex ligation-dependent probe amplification identifies copy number changes in normal and undetectable karyotype MDS patients

Jing Ma
Tianjin Tumor Hospital  https://orcid.org/0000-0002-0539-1544

xiaofei Ai
Chinese Academy of Medical Sciences Institute of Hematology and Blood Diseases Hospital

Jinhuan Wang
Tianjin Medical University Second Hospital

Limin Xing
Tianjin Medical University General Hospital

Chen Tian
Tianjin Tumor Hospital

Hongliang Yang
Tianjin Tumor Hospital

Yong Yu
Tianjin Tumor Hospital

Haifeng Zhao
Tianjin Tumor Hospital

Xiaofang Wang
Tianjin Tumor Hospital

Zhipang Zhao
Tianjin Tumor Hospital

Yafei Wang
Tianjin Tumor Hospital

Zeng Cao (caozeng1@sina.com)
https://orcid.org/0000-0003-1089-5808

Research article

Keywords: myelodysplastic syndromes, cytogenetic analysis, multiplex ligation-dependent probe amplification, normal karyotype, undetectable chromosome pattern

Posted Date: November 20th, 2020
Abstract

Background  Chromosomal abnormalities play an important role in classification and prognostication of myelodysplastic syndromes (MDS) patients. However, more than 50% low risk MDS patients harbor a normal karyotype. Recently, multiplex ligation-dependent probe amplification (MLPA) has emerged as an effective and robust method for the detection of cytogenetic aberrations in MDS patients.

Methods  To characterize the subset of MDS with normal karyotype or failed chromosome banding analysis, we analyzed 144 patient samples with normal karyotype or undetectable through regular chromosome banding, which were subjected to parallel comparison via fluorescence in situ hybridization (FISH) and MLPA.

Results  MLPA identifies copy number changes in 16.7% of 144 MDS patients and we observed a significant difference in overall survival (OS) (median OS: undefined vs 27 months, p=0.0071) in patients with normal karyotype proved by MLPA, versus aberrant karyotype cohort as determined by MLPA. Interestingly, patients with undetectable karyotype via regular chromosome banding indicated inferior outcome. Conclusion  Collectively, MDS patients with normal or undetectable karyotype via chromosome banding analysis can be further clarified by MLPA, providing more prognostic information that benefit for individualized therapy.

Background

Myelodysplastic syndrome (MDS) is a heterogeneous group of hematologic neoplasms classically described as a clonal disorder of hematopoietic stem cells leading to dysplasia and ineffective hematopoiesis in the bone marrow[1]. Chromosomal abnormalities play an important role in classification and prognostication of MDS patients, however, more than 50% low risk MDS patients harbor a normal karyotype as revealed by regular chromosome binding analysis[2-3]. While chromosome banding analysis can only detect gains and/or losses of more than 10 Mb size and it is depending on proliferation of the MDS clone to obtain metaphases in vitro. Therefore, it is necessary to find a more targeted, high-throughput, simple, and cost-effective method with higher resolution and accuracy targeting at the clinically relevant lesions which have been described in MDS patients.

Multiplex ligation-dependent probe amplification (MLPA) assay is a technique for copy number variation (CNV) identification in many human genes simultaneously. So far, over 300 probe sets specific for a very large range of genetic disorders are commercially available. MLPA is a multiplex polymerase chain reaction (PCR)-based technique that can quantify up to 50 different genomic targets simultaneously in a single experiment through amplification of specific hybridizing probes[4-7]. One of the major advantages is the high specificity, because this method can distinguish sequences differing in length by only one nucleotide. Another advantage is the low amount of input DNA (minimum of 20-50 ng) required for a successful MLPA reaction[8]. In this study we addressed the question whether MDS patients with normal
or without result after banding cytogenetics harbors cytogenetically cryptic gains or losses could be detected by MLPA.

**Methods**

**Patients and samples**

A total of 258 patients from January 2008 to December 2018 were retrospectively enrolled and were diagnosed with MDS according to the World Health Organization (WHO) Criterion 2016. Bone marrow samples at initial diagnosis of these patients were obtained. Among these patients, 144/258 (55.8%) cases showed either normal karyotype (n=132; 51.2%) or without result after banding cytogenetics (n=12; 4.6%). The male to female ratio was 1.48:1, and the median age of the patients was 53 years old (range: 15–83 years old) with the median follow-up time of 18 months (range: 2–101 months). Patients were given the informed consent to genetic analyses and laboratory data for research studies. The study was approved by the Medical Ethics Committee of Tianjin Cancer Institute and Hospital.

**Cytogenetic analysis**

Cytogenetic studies using standard G-banding techniques on heparinized BM samples were performed as part of the diagnostic work-up. At least 20 metaphase cells were analyzed whenever possible. Clonal abnormalities were defined as 2 or more cells with the same chromosomal gain or structural rearrangement or at least 3 cells with the same chromosomal deletion. Chromosome identification and karyotype descriptors used the International System for Human Cytogenetic Nomenclature (ISCN)[9].

**Interphase fluorescence in situ hybridization (FISH)**

FISH was performed on whole bone marrow mononuclear cells. In brief, Commercial, multicolor probes provided by Vysis laboratories (Abbott Laboratories, Illinois, USA) were used that included probes for -5/-5q, -7/-7q, +8, -20q and 17p- respectively. The following probes were used: LSI (locus-specific identifier) EGR1/D5S23, D5S721 Dual Color Probe for chromosome 5q; LSI D7S522/CEP 7 Probe for chromosome 7q; CEP (centromere enumeration probe) 8 DNA Probe for chromosome 8; LSI D20S108 Probe for chromosome 20q; and TP53 Probe for chromosome 17; all probes were obtained from Vysis Inc. (Downers Grove, IL, USA). The evaluation of FISH signals was performed using a fluorescence microscope (Olympus BX51, Japan) equipped with Q-FISH imaging software (IMSTAR, France). We counted 200–300 interphase nuclei for each slide. The positive threshold percentages were established according to previously published recommendations. The FISH results were interpreted in each institution by at least two experienced molecular pathologists, independent of concurrent metaphase karyotyping. Results were described according to the ISCN criteria[9].

**Multiplex ligation-dependent probe amplification (MLPA)**

Bone marrow specimens were collected from patients at diagnosis. Genomic DNA was extracted using the AxyPrep Blood Genomic DNA Miniprep Kit (Axygen Biosciences, cat no. AP-MN-BL-GDNA-250 Union
city, CA, USA). Fifty nanograms of gDNA were subjected to MLPA analysis by using SALSA MLPA P414-A1 MDS probe mix (MRC-Holland, Amsterdam, Netherlands). The probe mix contained 46 probes targeting at chromosomal regions of interest in MDS and 12 internal reference gene probes targeting at regions that are generally unchanged in MDS. MLPA reactions including internal quality controls and negative controls were performed according to the manufacturer instructions. The PCR products were analyzed using ABI 3130XL Genetic analyzer (Applied Biosystems, Foster City, CA, USA) and Coffalyser.net software (MRC Holland, Amsterdam, Netherlands) according to the manufacturer instruction.

**Statistical analysis**

Survival curves were plotted by the Kaplan-Meier method, and the difference was assessed by log-rank test. Overall survival (OS) was measured from the time of diagnosis to the date of death or last follow-up. The statistically significant difference was considered at p < 0.05.

**Results**

**Characterization of patients with normal karyotype or no result after banding cytogenetics**

As shown in Fig.1, normal karyotype and cases without result after banding cytogenetics are approximately 55.8%. MLPA identifies copy number changes in 24 (16.7% 24/144) patients. Among these 24 patients, 10 patients showed chromosome banding analysis failed. For patients with normal karyotype, 10.6% (14/132) were identified with CNVs. Characteristics of 144 patients were showed in Table 1. The 144 MDS patients were divided into four subgroups based on MLPA and karyotype results, there were 86 males and 58 females in our study. According to the classification of WHO 2016 version, the most common subtype is MDS-MLD. We calculated the Revised International Prognostic Scoring System scores (IPSS-R), confirming that 8 patients were very high risk, 28 patients with high risk, 48 patients with intermediate risk, 50 patients with low risk and 10 patients with very low risk disease.

**Abnormalities detected by MLPA in 14 MDS patients with normal karyotype**

Among 24 patients, 14 patients showed normal karyotype, which were showed in Table 2. According to cytomorphology, the cohort comprised the following MDS subtypes: MDS-RS (n=1), MDS-MLD (n=6), MDS-EB-1 (n=4), and MDS-EB-2 (n=3). The most common CNV was -17p (P53-4b, TP53-1).

Chromosome 8 abnormality was positive in 1 case (7.1%, 1/14), only showed with 8q amplification. Chromosome 5 abnormality was positive in 1 case (7.1%, 1/14). Chromosome 7 abnormality was positive in 1 case (7.1%, 1/14). Chromosome 20 abnormalities were positive in 3 cases (21.3%, 3/14). Chromosome 17 abnormalities including both 17p and 17q deletions were positive in 6 cases (42.9%, 6/14), 5 patients for 17p deletion and 1 patient for 17q deletion. Chromosome 11 abnormalities were positive in 2 cases (14.2%, 2/14) and both showed 11q amplifications. One patient was showed chromosome 19 abnormalities including both 19p and 19q deletions. All detected aberrations are summarized in Table 2.

**Abnormalities detected by MLPA in 10 MDS patients without result after banding cytogenetics**
Among 24 patients, 10 patients without result after banding cytogenetics were showed in Table 3. The cohort involved the following MDS subtypes: MDS-RS (n=1), MDS -MLD (n=6), MDS-EB-1 (n=2), MDS-EB-2 (n=1) and MDS-U (n=2). The most common CNVs were -7 and +8.

Chromosome 8 abnormalities including both 8p and 8q amplifications were positive in 4 cases (40%, 1/10). Chromosome 5 abnormalities were positive in 2 cases (20%, 2/10). Chromosome 7 abnormalities including both 7q deletion and 7p deletion were positive in 4 cases (40%, 4/10), two patients included both 7p and 7q deletions. Chromosome 20 abnormalities were not detected. Chromosome 17 abnormality was positive in 1 case (10%, 1/10). Chromosome 11 abnormality was positive in 1 case (10%, 1/10). One patient showed chromosome 19 abnormalities including both 19p and 19q deletions. All detected aberrations are summarized in Table 3.

**Comparison of MLPA assay and FISH**

To evaluate the performance of MLPA as a candidate method for the identification of CNVs in MDS patients, five abnormalities, including -5/-5q, -7/-7q, +8, -20q and 17p- were detected by both FISH and MLPA. FISH results of 144 cases were studied and compared with MLPA results. Among 144 MDS patients, 137 results were concordant, and the whole consistency was 95.1%. The genetic lesions determined by FISH and MLPA were listed in Table 4. Using MLPA analysis, clonal cytogenetic abnormalities were detected in 24 MDS patients with normal and undetectable karyotype, and 19/24 (79.2%) of those patients were reclassified into a higher-risk IPSS-R prognostic category. Using FISH, about 62.5% (15/24) of MDS patients had chromosomal abnormalities, whereas MLPA analysis detected that 100% (24/24) of MDS cases contained at least one CNV. For Patient 8 and Patient 17, MLPA analysis detected two CNVs and three CNVs, respectively. All the additional detected aberrations by MLPA are summarized in Table 4.

**Survival analysis**

We performed survival analysis and compared the outcome of patients with normal and cases without result after banding cytogenetics, which were also confirmed by MLPA (n=120) versus patients with aberrant karyotype as determined by MLPA (n=24). We observed a significant difference in survival (median OS: undefined vs 27 months, p=0.0071, Fig.2). We performed a survival analysis of normal karyotypes and cases without result after banding cytogenetics, respectively. Data were shown in Supplement Fig.1. We can see that, for patients with normal karyotype and patients with failed karyotype, there was no statistically significant difference (p=0.1877, p=0.2864) in the impact of MLPA results on OS. However, the curves of the two groups were clearly separated, and perhaps the difference was statistically significant with the increase in the number of patients enrolled.

In addition, we compared the outcome of patients with normal karyotype (n=132) to patients without result after banding cytogenetics (n=12). Our result showed a significant difference in survival (median OS: undefined vs 26 months, p=0.0059, Fig.3), indicating that patients without result after banding cytogenetics had worse survival.
In our study, we also explored the impact of cytogenetic aberrations detected by MLPA on OS of lower-risk and higher-risk patients (defined according to IPSS-R) with a normal or without result after banding cytogenetics via R-banding test. Lower-risk IPSS-R group included very low risk patients, low risk patients and intermediate patients with score ≤ 3.5. Higher-risk IPSS-R group included intermediate patients with score > 3.5, high risk, and very high risk patients. For lower-risk IPSS-R patients (73/144), there were no differences in OS (P=0.5207; Fig.4A). For higher-risk IPSS-R patients (71/144), OS was significantly shorter in the higher-risk patients (n=19) with cytogenetic aberrations detected using MLPA compared with other higher-risk patients n=52 (median OS: 21 vs. undefined months, P=0.0281; Fig. 4B).

Discussion

In MDS, the IPSS-R classifiers have clearly demonstrated the prognostic impact of distinct cytogenetic abnormalities, these cytogenetic abnormalities include -7/7q-, -5/5q-, +8, 20q-, -Y, i(17q) or t(17p), -13/13q-, 11q-, 12p- or t(12p), and the most common abnormalities (-7/7q-, -5/5q-, +8 and 20q-) occur in approximately 40% of MDS cases[10,11]. The majority of chromosome aberrations in MDS are gains and deletions of chromosomal material while balanced rearrangements are rare[3]. As we all know, more than 50% of MDS showed a normal karyotype. For MDS patients with normal karyotype, FISH is increasingly used for cytogenetic analysis because of its higher resolution and greater success rate. Nevertheless, it is difficult for FISH to screen all lesions simultaneously due to the high cost and technique limitation. Although established as the golden standard for detection of chromosomal aberrations in MDS, karyotyping (which requires cell amplification) and FISH are low-resolution, time consuming, labor-intensive and costly assays compared to MLPA. While small probes are directed at regions of interest in MDS, providing a resolution higher than that of FISH and bacterial artificial chromosome (BAC)-based array comparative genomic hybridization (aCGH), and equivalent to oligo-based aCGH[6,7]. MLPA has a considerably higher resolution and can identify small unbalanced chromosomal aberrations undetectable by chromosome banding analysis.

Donahue et al[12] showed that MLPA has higher accuracy and specificity than FISH in MDS and ALL patients. Array CGH and MLPA have been increasingly used as a method of choice for diagnosis of MDS patients with unexplained genetic aberrations. Volkert et al [13] detected CNVs in 11% of 520 MDS patients with a normal karyotype using array CGH. Wang et al[14] analyzed 437 MDS patients using an MLPA assay and detected clonal genetic abnormalities in 9.2% of cases with a normal or failed karyotype. In our study, we analyzed 258 MDS patients using MLPA assay and detected clonal genetic abnormalities in 16.7% of normal or failed karyotype patients. In our cohort, the proportion of patients with CNVs was higher, probably because of the higher proportion of patients with karyotype failure. For normal karyotype, MLPA detected clonal genetic abnormalities in 10.6% of 132 patients. Among 144 MDS patients, the whole consistency of FISH and MLPA was 95.1%, and no patient showed cytogenetic abnormalities solely by FISH. Our results provide evidence that MLPA has an advantage over FISH for MDS patients.
As we all know, chromosome banding analysis is very important for MDS. Unfortunately, a variety of issues hamper cytogenetic evaluation in cases because chromosome banding studies may be hindered by several factors, including low proliferative rate in tissue culture, insufficient number of metaphase cells, reduced cell viability or hypocellularity upon arrival to the reference laboratory, poor chromosome morphology or complexity of the karyotype[15,16]. So the outcomes of these patients were poorly understood. In our study, 4.6% of MDS patients without result via regular chromosome band analysis, while we indicated that these patients may encounter a poor outcome as detected by MLPA(Fig.3). On the other hand, the significance of failed banding cytogenetics on outcome of MDS patients has been scarcely reported. Medeiros et al [17] compared the baseline characteristics and the prognostic impact of 94 (6%) AML patients without result after banding cytogenetics to the remaining 1403 AML patients with successful karyotype. These patients without result after banding cytogenetics had a lower response rate to induction chemotherapy and the complete remission and survival rates were similar to those seen in patients with unfavorable karyotype. Lazarevic et al[18]analyzed 1737 AML patients, the frequencies of unsuccessful cytogenetics and unperformed cytogenetics were 2.1% and 20%, respectively. Their research showed that a lack of cytogenetic data translates into a poor prognosis. Our findings support this observation that patients with failed karyotype should be considered higher-risk patients. Together, new techniques such as MLPA should be used to overcome the technical challenges associated with cases without result after banding cytogenetics.

For the impact of cytogenetic aberrations detected by MLPA, as shown in Fig.2,OS in 24 patients harboring abnormalities detected solely by MLPA was significantly shorter compared to all others. The impact of cytogenetic aberrations detected by MLPA on OS of different IPSS-R patients were also showed in Fig.4. These results are consistent with the study of Wang [16]. All those suggest that MPLA has the potential to alter the risk stratification in MDS patients with normal or cases without result after banding cytogenetics.

**Conclusion**

In conclusion, MLPA can detect CNVs in a high throughput fashion with higher resolution and can be used easily in routine diagnostics in MDS with normal karyotype or cases without result after banding cytogenetics, benefiting to the patients harboring submicroscopic deletions where informative prognostic factors underlying.

**Declarations**

**Ethics approval and consent to participate**

The study was approved by the Medical Ethics Committee of Tianjin Cancer Institute and Hospital. Because our study is retrospective, and we collected and analyzed the data of enrolled patients by reviewing their electronic medical records. Informed consent was obtained orally from the included
patients by telephone. The information of enrolled patients is anonymous. The collection, analysis and publication of the data will not infringe enrolled patients’ health, safety and privacy.

**Consent for publication**

Not applicable.

**Availability of data and materials**

Please contact the author for data requests.

**Competing interests**

The authors declare that they have no competing interests.

**Funding**

This study was funded by the National Natural Science Foundation of China (grant 81870150), the National Natural Science Foundation of China (grant 81670102), the National Natural Science Foundation of China (grant 81670104).

**Authors’ contributions**

J.M and A.F drafted the paper, A.F, J.M, L.X ,X.A and C.T provided patient information, J.M,H.Y and Y.Y analyzed data, H.Z,Z,Z, and X.W revised the paper Y.W and Z.C designed the research study and critically revised the paper. All authors approved all versions including the final version and are responsible for the accuracy and integrity of all aspects of the manuscript.

**Acknowledgements**

None.

**Author details**

1 Department of Hematology and Blood and Marrow Transplantation, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer. Tianjin’s Clinical Research Center for Cancer. Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.

2 Department of Pathology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.

3 Department of Oncology, The Second Hospital of Tianjin Medical University

4 Hematology department of General Hospital, Tianjin Medical University , Tianjin , China.
Abbreviations

MLPA: multiplex ligation-dependent probe amplification; FISH: fluorescence in situ hybridization

OS: overall survival; CNV: copy number variation; IPSS-R: Revised International Prognostic Scoring System; AML: acute myelocytic leukemia; ALL: acute lymphoblastic leukemia.

References

1. Banerjee T, Calvi LM, Becker MW, Liesveld JL. Flaming and fanning: The Spectrum of inflammatory influences in myelodysplastic syndromes. Blood Rev. 2019; 36: 57-69.
2. Gadji M, Pozzo AR. From cellular morphology to molecular and epigenetic anomalies of myelodysplastic syndromes. Genes Chromosomes Cancer. 2019; 58(7): 474-483.
3. Haase D. Cytogenetic features in myelodysplastic syndromes. Ann Hematol. 2008; 87(7): 515-526.
4. Schouten JP, McElgunn CJ, Waaijer R, Zwijnenburg D, Diepvens F, Pals G. Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res. 2002; 30(12): 57.
5. Fabris S, Scarciolla O, Morabito F, Cifarelli RA, Dininno C, Cutrona G, Matis S, Recchia AG, Gentile M, Ciceri G, Ferrarini M, Ciancio A, Mannarella C, Neri A, Fragasso A. Multiplex ligation-dependent probe amplification and fluorescence in situ hybridization to detect chromosomal abnormalities in chronic lymphocytic leukemia: a comparative study. Genes Chromosomes Cancer. 2011; 50(9): 726-734.
6. den Dunnen JT, White SJ. MLPA and MAPH: sensitive detection of deletions and duplications. Curr Protoc Hum Genet. 2006; Chapter 7: Unit7.14.
7. Neill NJ, Torchia BS, Bejjani BA, Shaffer LG, Ballif BC. Comparative analysis of copy number detection by whole-genome BAC and oligonucleotide array CGH. Mol Cytogenet. 2010; 3:11.
8. Xing R, Li C, Gale RP, Zhang Y, Xu Z, Qin T, Li B, Fang L, Zhang H, Pan L, Hu N, Qu S, Xiao Z. Monosomal karyotype is an independent predictor of survival in patients with higher-risk myelodysplastic syndrome. Am J Hematol. 2014; 89(10):163-168.
9. Shaffer LG, Slovak ML, Campbell LJ. ISCN 2009: An international system for human cytogenetic nomenclature (2009): Recommendations of the International Standing Committee on Human Cytogenetic Nomenclature. Basel: Karger.
10. Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sole F. Revised International Prognostic Scoring System (IPSS-R) for myelodysplastic syndromes. Blood. 2012; 120:2454-2465.
11. Kearney L, Horsley SW. Molecular cytogenetics in hematological malignancy: current technology and future prospects. Chromosoma. 2005; 14(4):286-94.
12. Donahue A, Abdool A, Gaur R, Wohlgemuth JG, Yeh CH. Multiplex ligation-dependent probe amplification for detection of chromosomal abnormalities in myelodysplastic syndrome and acute myeloid leukemia. Leuk Res. 2011; 35(11):1477-1483.
13. Volkert S, Haferlach T, Holzwarth J, Zenger M, Kern W, Staller M, Nagata Y, Yoshida K, Ogawa S, Schnittger S, Haferlach C. Array CGH identified copy number changes in 11% of 520 MDS patients with normal karyotype and uncovers prognostically relevant deletions. Leukemia. 2016; 30(1): 257-260.

14. Wang J, Ai X, Qin T, Xu Z, Zhang Y, Liu J, Li B, Fang L, Zhang H, Pan L, Hu N, Qu S, Cai W, Ru K, Jia Y, Huang G, Xiao Z. Multiplex ligation-dependent probe amplification assay identifies additional copy number changes compared with R-band karyotype and provide more accuracy prognostic information in myelodysplastic syndromes. 2017; 8(1):1603-1612.

15. Watson MS. Quality assurance and quality control in clinical cytogenetics. Current Protocols in Human Genetics. New York, John Wiley. 2007; 8.2.1-8.2.9.

16. Santos MFM, Oliveira FCAC, Kishimoto RK, Borri D, Santos FPS, Campregher PV, Silveira PAA, Hamerschlak N, Mangueira CLP1, Duarte FB, Cepaldi AH, Salvino MA, Velloso EDRP. Pre-analytical parameters associated with unsuccessful karyotyping in myeloid neoplasm: a study of 421 samples. Braz J Med Biol Res. 2019; 52(2):8194-8198.

17. Medeiros BC, Othus M, Estey EH, Fang M, Appelbaum FR. Unsuccessful Diagnostic Cytogenetic Analysis Is a Poor Prognostic Feature in Acute Myeloid Leukaemia. Br J Haematol. 2014; 164(2):245-250.

18. Lazarevic V, Hörstedt AS, Johansson B, Antunovic P, Billström R, Derolf Å, Lehmann S, Möllgård L, Peterson S, Stockelberg D, Uggla B, Vennström L, Wahlin A, Höglund M, Juliusson G. Failure matters: unsuccessful cytogenetics and unperformed cytogenetics are associated with a poor prognosis in a population-based series of acute myeloid leukaemia. Eur J Haematol. 2015; 94(5):419-423.

Tables

Table 1 Characteristics MDS Patients in our study (n=144)
|                                      | Total n (%) | Normal karyotype and MLPA+ | Normal karyotype and MLPA- | Failed karyotype and MLPA+ | Failed karyotype and MLPA- |
|-------------------------------------|-------------|----------------------------|----------------------------|-----------------------------|-----------------------------|
| Total n of patients                 | 144 (100%)  | 14                         | 118                        | 10                          | 2                           |
| Median age (years)                  | 53          | 47.5                       | 57                         | 44                          | 51                          |
| Sex                                 |             |                            |                            |                             |                             |
| Male                                | 86 (59.7%)  | 13                         | 66                         | 6                           | 1                           |
| Median Hgb (g/L)                    | 76          | 72                         | 81                         | 76                          | 79                          |
| Median ANC ($\times 10^9$/L)        | 1.2         | 1.0                        | 1.1                        | 0.9                         | 1.2                         |
| Median platelet count ($\times 10^9$/L) | 72          | 89                         | 76                         | 64                          | 70                          |

WHO 2016

|                                      |             |                            |                            |                             |                             |
| MDS-SLD                              | 1 (0.7%)    | 0                          | 1                          | 0                           | 0                           |
| MDS-RS                               | 6 (4.2%)    | 1                          | 4                          | 1                           | 0                           |
| MDS-MLD                              | 68 (47.2%)  | 6                          | 56                         | 4                           | 2                           |
| MDS-EB-1                             | 33 (22.9%)  | 4                          | 27                         | 2                           | 0                           |
| MDS-EB-2                             | 29 (20.1%)  | 3                          | 25                         | 1                           | 0                           |
| MDS-U                                | 7 (4.9%)    | 0                          | 5                          | 2                           | 0                           |

PSS-R risk category

|                                      |             |                            |                            |                             |                             |
| Very low                             | 10 (7.0%)   | 2                          | 8                          | 0                           | 0                           |
| Low                                  | 50 (34.7%)  | 6                          | 42                         | 2                           | 0                           |
| Intermediate                         | 48 (33.3%)  | 1                          | 46                         | 1                           | 0                           |
| High                                 | 28 (19.4%)  | 4                          | 16                         | 6                           | 2                           |
| Very high                            | 8 (5.6%)    | 1                          | 6                          | 1                           | 0                           |

**Table 2**

Copy number changes identified by MLPA in 14 MDS patients with normal karyotype
| Case | Age | Gender | Diagnosis | Karyotype based on MLPA | Assumed karyotype according to MLPA |
|------|-----|--------|-----------|-------------------------|------------------------------------|
| Patient 169 | 69 | Male | MDS-EB-111q(4): KMT2A-4,KMT2A-36,TIRAP-3,ETS1-10 | + 11q |
| Patient 272 | 72 | Male | MDS-RS | 11q(4): KMT2A-4,KMT2A-36,TIRAP-3,ETS1-10 | + 11q |
| Patient 350 | 50 | Male | MDS-MLD | 20q(1): ASXL1-4 | -20q |
| Patient 463 | 39 | Male | MDS-EB-28q(3): NCOA2-5,MYC-3,PTK2-33 | 17p(2): TP53-4b,TP53-1 | + 8q -17p |
| Patient 939 | 36 | Male | MDS-MLD | 17p(2): TP53-4b,TP53-1 | -17p |
| Patient 10 | 46 | Male | MDS-MLD | 17p(3): TP53-10,TP53-4b,TP53-1 | -17p |
| Patient 11 | 51 | Male | MDS-EB-217p(2): TP53-4b,TP53-1 | -17p |
| Patient 12 | 42 | Male | MDS-MLD | 11q(1): KMT2A-4(+) 17q(1): NF1-17 SUZ12-12(+) | -17p |
| Patient 13 | 34 | Female | MDS-EB-219p(1):SMARCA4-25 19q(1): PRPF31-14 | -19 |
| Patient 14 | 32 | Male | MDS-MLD | 20q(2):MMP9-9,ZMYND8-14 | -20q |
| Patient 16 | 57 | Male | MDS-EB | 120q(3): ASXL1-4,SRC-6,ZMYND8-14 | -20q |
| Patient 19 | 47 | Female | MDS-MLD | 5q(3):APC-18,EGR1-1,EGR1-2 | -5q |
| Patient 24 | 61 | Female | MDS-EB-17q(4): CDK6-8 SAMD9L-5,MLL5-4,MET-13 | -7q |

Table 3
Copy number changes identified by MLPA in 10 MDS patients with failed chromosome banding analysis.
| Case | Age | Gender | Diagnosis | Karyotype based on MLPA | Assumed karyotype according to MLPA |
|------|-----|--------|-----------|------------------------|-----------------------------------|
| Patient 81 | 58 | Male | MDS-EB-1 | 8p(1): FGFR1-2 8q(4): NCOA2-5,RUNX1T1-8, MYC-3, PTK2-33+ 8 | |
| Patient 49 | 64 | Male | MDS-MLD8p(1): FGFR1-2 8q(4): NCOA2-5,RUNX1T1-8,MYC-3,PTK2-33 + 8 | |
| Patient 50 | 75 | Male | MDS-EB-1 | 8p(1): FGFR1-2 8q(4): NCOA2-5, RUNX1T1-8,MYC-3,PTK2-33 + 8 | |
| Patient 42 | 88 | Male | MDS-MLD8p(1): FGFR1-2 8q(4): NCOA2-5, RUNX1T1-8,MYC-3,PTK2-33 + 8 +11q | 11q(1): KMT2A-4 |
| Patient 39 | 175 | Female | MDS-U | 5q(3): EGR1-1,EGR1-2,RPS14-3 17p(3):TP53-10,TP53-4b,TP53-1 19p(1):SMARCA4-25 19q(1): PRPF31-14 | -5q -17p -19 |
| Patient 48 | 18 | Male | MDS-MLD5q(4): EGR1-1,MIR145-1,SPARC-7,SPARC-1 | -5q |
| Patient 37 | 20 | Female | MDS-U | 7p(1): IKZF1-30 7q(7):CDK6-8,SAMD9L-5,EPO-4,MLL5-4,MET-13,EZH2-20,EZH2-13 | -7 |
| Patient 41 | 21 | Male | MDS-MLD7p(1): IKZF1-30 7q(7): CDK6-8,SAMD9L-5,EPO-4,MLL5-4,MET-13,EZH2-20,EZH2-13 | -7 |
| Patient 41 | 22 | Male | MDS-EB-27q(3): CDK6-8,MLL5-4,MET-13 | -7q |
| Patient 67 | 23 | Male | MDS-RS | 7q(5): CDK6-8,MLL5-4,MET-13,EZH2-20,EZH2-13 | -7q |

Table 4
Genetic lesions determined by FISH and MLPA
| Case   | Diagnosis | IPSS-R risk | karyotype | FISH | MLPA | IPSS-R risk group by MLPA |
|--------|-----------|-------------|-----------|------|------|--------------------------|
| Patient 5 | MDS-EB-1 | Very high  | failed    | +8   | +8   | Very high                |
| Patient 6 | MDS-MLD  | High       | failed    | +8   | +8   | Very high                |
| Patient 7 | MDS-EB-1 | High       | failed    | +8   | +8   | Very high                |
| Patient 8 | MDS-MLD  | High       | failed    | +8   | +8 +11q | Very high              |
| Patient 18 | MDS-MLD | High       | failed    | -5q  | -5q  | High                     |
| Patient 20 | MDS-U   | Intermediate | failed   | -7   | -7   | Very high                |
| Patient 22 | MDS-EB-2 | High       | failed    | -7q  | -7q  | Very high                |
| Patient 23 | MDS-RS  | Low        | failed    | -7q  | -7q  | Very high                |
| Patient 17 | MDS-U   | Intermediate | failed   | -5q  | -5q -17p -19 | Very high          |
| Patient 24 | MDS-EB-1 | High       | failed    | -7q  | -7q  | Very high                |
| Patient 9  | MDS-MLD  | Low        | normal    | -17p | -17p | High                     |
| Patient 10 | MDS-MLD  | Low        | normal    | -17p | -17p | High                     |
| Patient 15 | MDS-MLD  | Low        | normal    | -20q | -20q | Low                      |
| Patient 16 | MDS-EB-1 | Low        | normal    | -20q | -20q | Intermediate             |
| Patient 21 | MDS-MLD  | High       | failed    | Negative* -7 | Very high  |
| Patient 1 | MDS-EB-1  | High       | normal    | Negative + 11q | High      |
| Patient 2  | MDS-RS    | High       | normal    | Negative + 11q | High      |
| Patient 3  | MDS-MLD  | Very low   | normal    | Negative -20q | Low       |
| Patient 11 | MDS-EB-2  | Low        | normal    | Negative -17p | High      |
| Patient 12 | MDS-MLD  | Very low   | normal    | Negative -17p | Low       |
| Patient 13 | MDS-EB-1  | Intermediate | normal  | Negative -17q | Very high |
| Patient 14 | MDS-EB-2  | Low        | normal    | Negative -19 | Intermediate |
| Patient 19 | MDS-MLD  | High       | normal    | Negative -5q | Very high  |

*Negative just for -5/-5q, -7/-7q, +8, -20q and 17p-.
Figures

MDS patients enrolled from January 2008 to December 2018

n= 258

Chromosome Banding Analysis

normal karyotype
n=132; 51.2%

aberrant karyotype
n=114; 44.2%

karyotype failed
n=12; 4.6%

MLPA

aberrant
n=14; 10.6%

normal
n=118; 89.4%

MLPA

aberrant
n=10; 83.3%

normal
n=2; 16.7%

Figure 1

Diagnostic approach in 258 MDS patients. Distribution of patients with aberrant karyotype, normal cytogenetics, and failed chromosome banding analysis are depicted.
Figure 1

Diagnostic approach in 258 MDS patients. Distribution of patients with aberrant karyotype, normal cytogenetics, and failed chromosome banding analysis are depicted.
Figure 2

OS analysis of patients harboring aberration (n=24) or not detected (n=120) by MLPA in 144 MDS patients with normal and failed karyotype
Figure 2

OS analysis of patients harboring aberration (n=24) or not detected (n=120) by MLPA in 144 MDS patients with normal and failed karyotype.
Figure 3

OS of patients with normal karyotype (n=132) and failed chromosome banding analysis (n=12).

p=0.0059
Figure 3

OS of patients with normal karyotype (n=132) and failed chromosome banding analysis (n=12).
Figure 4

OS of patients with cytogenetic aberrations detected using MLPA compared with other patients in lower risk IPSS-R group (A MLPA+ n=5 MLPA- n=68) and higher risk IPSS-R group (B MLPA+ n=19 MLPA- n=52).
Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- dataset.pzf
- dataset.pzf
- supplementfigure1.tif
- supplementfigure1.tif